Emily
Editor, Senior Moderator
https://www.sciencedirect.com/scienc...85253821008255
Better Late than Never: Eventual Seroconversion against SARS-CoV-2 in a Kidney Transplant Recipient after Repeated Immune Challenge and Monoclonal Antibody Therapy.
Author: Julien De Greef,Arnaud Devresse,Imane Saad Albichr,Anais Scohy,Nada Kanaan,Hélène Georgery,Leila Belkhir,Benoit Kabamba,Jean Cyr Yombi,Eric Goffin
Publication: Kidney International
Publisher:Elsevier
Date:Available online 31 August 2021
© 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.
Kidney transplant recipients (KTRs) are disproportionately affected by COVID-19. In addition to limited therapeutic options, concerns have arisen regarding poor vaccine efficacy in this population.[SUP]1[/SUP]
We report the case of a 64-year-old KTR treated with an association of tacrolimus, mycophenolate mofetil (MMF) and steroids who developed a second SARS-CoV-2 infection one year after a first COVID-19 episode, and 55 days after receiving his second BNT162b2-mRNA vaccine injection. Three days after the onset of isolated fever, high viral load of SARS-CoV-2 gamma variant was detected through RT-PCR in a nasopharyngeal swab (Table 1). MMF was interrupted and intravenous monoclonal antibodies (casirivimab 1200mg and imdevimab 1200mg, Regeneron, USA) therapy was given. Clinical and virological evolutions were favorable: viral load decreased <1000 copies/mL on day 8 and was eventually negative on day 28 after perfusion (Table 1). Interestingly, an anti-N native antibody seroconversion was observed on day 28 (Table 1). Notably, three serologic tests had been performed before the second SARS-CoV-2 infection (including one 43 days after the second vaccine dose injection) and were all negative for both anti-N and anti-RBD antibody.
Better Late than Never: Eventual Seroconversion against SARS-CoV-2 in a Kidney Transplant Recipient after Repeated Immune Challenge and Monoclonal Antibody Therapy.
Author: Julien De Greef,Arnaud Devresse,Imane Saad Albichr,Anais Scohy,Nada Kanaan,Hélène Georgery,Leila Belkhir,Benoit Kabamba,Jean Cyr Yombi,Eric Goffin
Publication: Kidney International
Publisher:Elsevier
Date:Available online 31 August 2021
© 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.
Kidney transplant recipients (KTRs) are disproportionately affected by COVID-19. In addition to limited therapeutic options, concerns have arisen regarding poor vaccine efficacy in this population.[SUP]1[/SUP]
We report the case of a 64-year-old KTR treated with an association of tacrolimus, mycophenolate mofetil (MMF) and steroids who developed a second SARS-CoV-2 infection one year after a first COVID-19 episode, and 55 days after receiving his second BNT162b2-mRNA vaccine injection. Three days after the onset of isolated fever, high viral load of SARS-CoV-2 gamma variant was detected through RT-PCR in a nasopharyngeal swab (Table 1). MMF was interrupted and intravenous monoclonal antibodies (casirivimab 1200mg and imdevimab 1200mg, Regeneron, USA) therapy was given. Clinical and virological evolutions were favorable: viral load decreased <1000 copies/mL on day 8 and was eventually negative on day 28 after perfusion (Table 1). Interestingly, an anti-N native antibody seroconversion was observed on day 28 (Table 1). Notably, three serologic tests had been performed before the second SARS-CoV-2 infection (including one 43 days after the second vaccine dose injection) and were all negative for both anti-N and anti-RBD antibody.